TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31868201
Drug: mLP formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: mLP formula (1.7 g protein/100 kcal)
Study: 31868201
Drug: CTRL formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTRL formula (2.1 g protein/100 kcal)
Study: 21385806
Drug: Weekly administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly administration of low dose, high frequency ultrasound therapy (0.5 W/cm², 1 MHz, pulsed pattern of 1:4) for up to 12 weeks plus standard care
Study: 21385806
Drug: Weekly administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly administration of low dose, high frequency ultrasound therapy
Study: 9366940
Drug: Eltanolone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltanolone (0.2 mg/kg in elderly, 0.3 mg/kg in young)
Study: 1394027
Drug: RIMA compounds
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIMA compounds (including moclobemide)
Study: 28348152
Drug: SAL200 (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAL200 (0.1, 0.3, 1, 3, and 10 mg/kg of body weight)
Study: 24223034
Drug: Desmopressin 0.2
Normalized name: DESMOPRESSIN 0.2MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin 0.2 mg nocte
Study: 18714152
Drug: L-carnitine 1
Normalized name: L-Carnitine 1,000mg Oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine 1 g orally 3 times a day for 4 weeks
Study: 17138063
Drug: Alemtuzumab induction
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab induction therapy followed by FK506 monotherapy
Study: 17138063
Drug: Conventional immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunosuppression (FK506, mycophenolate mofetil and steroids) without any induction agent
Study: 14633147
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) enoxaparin
Study: 8942591
Drug: Sitting position
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitting position during IT injection of dextrose-free bupivacaine 0.25% with fentanyl 0.005%
Study: 8942591
Drug: Lateral position
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral position during IT injection of dextrose-free bupivacaine 0.25% with fentanyl 0.005%
Study: 7043116
Drug: Concurrent feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent feedback from utilization review coordinators
Study: 30785851
Drug: DPT‐IPV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPT‐IPV vaccine co‐administered with HRV vaccine
Study: 30785851
Drug: DPT‐IPV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPT‐IPV vaccine staggered with HRV vaccine
Study: 30227610
Drug: Marine n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine n-3 PUFA (2 g daily for three months)
Study: 26847975
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Analysis System of Psychotherapy (CBASP) plus Treatment As Usual (TAU), n=8
Study: 26847975
Drug: Mindfulness-based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based Cognitive Therapy (MBCT) plus Treatment As Usual (TAU), n=9
Study: 26847975
Drug: Treatment As
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment As Usual (TAU) only, n=8
Study: 17620076
Drug: Grazax sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazax sublingual immunotherapy
Study: 1710098
Drug: Aprotinin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (4 x 10(6) KIU) as a continuous infusion and 2 x 10(6) KIU added to pump prime
Study: 28716146
Drug: Weekly mobile
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly mobile phone text messaging plus motivational interviewing and usual standard of care
Study: 21289601
Drug: acamprosate (2997
Approvals — FDA: no, EMA: no, PMDA: no
Description: acamprosate (2997 mg daily)
Study: 19712767
Drug: CpG-containing malaria
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: CpG-containing malaria vaccine
Study: 17200316
Drug: Alendronate (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (70 mg orally per week for three months)
Study: 17200316
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (Control Group B)
Study: 1426388
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate plus gonadotropins (group L)
Study: 30545350
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (long-acting muscarinic antagonist and long-acting β2-agonist/inhaled corticosteroid)
Study: 30545350
Drug: Dual bronchodilator
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual bronchodilator (ICS withdrawal)
Study: 23818351
Drug: XELOX chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: XELOX chemotherapy (3 cycles)
Study: 16699814
Drug: 1 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg/day Pycnogenol
Study: 10957700
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg ibuprofen per os and topical placebo
Study: 10957700
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of a 5% commercial ibuprofen gel topically applied and oral placebo capsules
Study: 10957700
Drug: Peroral ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Peroral ibuprofen
Study: 10957700
Drug: Commercial ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Commercial ibuprofen gel
Study: 8771007
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 4 IU/m2/day subcutaneously for 6 months
Study: 6730991
Drug: Community treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community treatment provided by the Community Treatment Team, including comprehensive community treatment and a 24-h crisis service.
Study: 6730991
Drug: Community treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community treatment (Experimental group).
Study: 30044162
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg daily combined with metformin 500 mg three times daily (Group A)
Study: 30044162
Drug: Simvastatin and
Normalized name: simvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin and metformin individually (Group B)
Study: 30044162
Drug: Simvastatin and
Normalized name: simvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin and metformin individually (Group C)
Study: 20697836
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (IIT) to maintain blood glucose levels from 80 to 110 mg/dl
Study: 20697836
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment to maintain blood glucose levels less than 151 mg/dl
Study: 11892710
Drug: Neridronate 200
Normalized name: Neridronate
DrugBank: Neridronic Acid (DB11620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neridronate 200 mg
Study: 11892710
Drug: Neridronate 100
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neridronate 100 mg
Study: 11892710
Drug: All Neridronate
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All Neridronate doses
Study: 8967094
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) infusion at a dosage of 60 micrograms over 2 hours
Study: 4048832
Drug: Secretin infusion
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Secretin infusion (3 CU/kg/h)
Study: 20692797
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise therapy (SET) with at least two training sessions per week, each lasting over 30 minutes during the first 3 months.
Study: 20692797
Drug: SET involving
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SET involving only walking vs. a combination of exercises.
Study: 15906080
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in VO2max from 2.36 l min(-1) to 3.44 l min(-1)
Study: 15906080
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in VO2max from 4.77 l min(-1) to 6.36 l min(-1)
Study: 7589684
Drug: Mast cell
Normalized name: Mast cell protease 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mast cell blocker (tranilast) 300 mg/d for 3 months
Study: 2404878
Drug: 6‐monthly screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6‐monthly screening by chest X‐ray and sputum cytology
Study: 7364521
Drug: No induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: No induction (control) treatment
Study: 25350973
Drug: Raltegravir with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir with optimized background therapy (OBT)
Study: 23497575
Drug: Complex multifaceted
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex multifaceted intervention incorporating academic detailing, medicines review with web-based pharmaceutical treatment algorithms, and tailored patient information leaflets.
Study: 20449934
Drug: Oral rapamycin
Normalized name: kanamycin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rapamycin plus bare metal stents (OR + BMS)
Study: 28168845
Drug: Drug eluting
Normalized name: Drug eluting stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug eluting stents (DES)
Study: 9431344
Drug: Early operation
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early operation compared with intravenous antibiotics with or without drainage
Study: 9431344
Drug: Delay in
Normalized name: Delayed Release Oral Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delay in treatment
Study: 8172795
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (timing of quality of life assessment)
Study: 25596659
Drug: Chemoradiotherapy (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (two cycles of cisplatin 100 mg/m(2) during radiotherapy)
Study: 25596659
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus panitumumab (three cycles of panitumumab 9 mg/kg every 3 weeks administered with radiotherapy)
Study: 17608028
Drug: FavId, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: FavId, a patient-specific idiotypic vaccine
Study: 11252687
Drug: Rofecoxib (Vioxx)
Normalized name: rofecoxib Oral Suspension [Vioxx]
DrugBank: Rofecoxib (DB00533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rofecoxib (Vioxx) 12.5 mg qd
Study: 11252687
Drug: Arthrotec (diclofenac
Normalized name: Arthrotec (diclofenac sodium (enteric coated core) 50 MG / miSOPROStol (non-enteric coated mantle) 200 MCG) Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrotec (diclofenac 50 mg/misoprostol 200 mcg bid)
Study: 7997000
Drug: 0.3% d-phenothrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% d-phenothrin lotion
Study: 11027424
Drug: CarboMIP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CarboMIP regimen (cisplatin 60 mg m(‐2) and carboplatin 200 mg m(‐2) with mitomycin 6 mg m(‐2) and ifosfamide 3 g m(‐2))
Study: 11027424
Drug: MIP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIP regimen (cisplatin 50 mg m(‐2) with mitomycin 6 mg m(‐2) and ifosfamide 3 g m(‐2))
Study: 8017600
Drug: Continuous regional
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous regional analgesia (interpleural and epidural infusions)
Study: 8017600
Drug: Intravenous opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous opioid administration
Study: 3065741
Drug: Chlorambucil (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorambucil (daily indefinite course)
Study: 16131531
Drug: Morphine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (100 microg/kg + 10 microg/kg/h)
Study: 16131531
Drug: Additional morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional morphine
Study: 11084248
Drug: Aflurax (pectin-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflurax (pectin-based anti-reflux formulation)
Study: 27465906
Drug: Enteric-coated formulation
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated formulation
Study: 27465906
Drug: Second formulation
Normalized name: 60 Second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second formulation prototype (single-unit core and enteric-coating film)
Study: 23740231
Drug: Naproxen (NPX)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen (NPX) 1000 mg/d
Study: 23039926
Drug: Multi-tiered oral
Normalized name: Finafta Multi Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-tiered oral health education programme
Study: 15835284
Drug: Modified Constraint-Induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Constraint-Induced Movement Therapy (m-CIMT)
Study: 12781934
Drug: Medication self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication self-management program
Study: 10475621
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy and bone marrow transplant with HLA-identical sibling donor
Study: 10475621
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy and bone marrow transplant with alternative donor (non-HLA-identical sibling)
Study: 10475621
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy and bone marrow transplant with autotransplant
Study: 10475621
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (interferon and/or chemotherapy)
Study: 6126894
Drug: Metipranolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metipranolol (5 mg)
Study: 6126894
Drug: Metipranolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metipranolol (20 mg)
Study: 31013204
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 mg/kg Dextrose)
Study: 29244251
Drug: B vitamin
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamin supplementation (folic acid 2.5 mg/day, vitamin B6 50 mg/day, vitamin B12 1 mg/day)
Study: 25833778
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg of anthocyanins twice daily
Study: 17220905
Drug: Fludarabine (Flu)
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (Flu) 40 mg/m(2)/day x 5 days
Study: 17220905
Drug: Cladribine (Clad)
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine (Clad) 10 mg/m(2)/day x 5 days plus oral busulfan (1 mg/kg q6 h x 2 days) and total body irradiation 200 cGy
Study: 15079003
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy (ERT) with agalsidase beta
Study: 2751738
Drug: Isosorbide‐5‐mononitrate sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide‐5‐mononitrate sustained-release capsules (Olicard 40 retard)
Study: 2751738
Drug: Standard‐release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard‐release formulation of isosorbide‐5‐mononitrate
Study: 155098
Drug: Timolol, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol, administered twice a day
Study: 155098
Drug: Pilocarpine, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine, administered four times a day
Study: 18346976
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) treatment
Study: 28130888
Drug: Warm lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm lidocaine and tetracaine patch
Study: 23157172
Drug: Low-salt treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-salt treatment 6.6 mg/m(3)
Study: 23157172
Drug: High-salt treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-salt treatment 10.8 mg/m(3)
Study: 23157172
Drug: Placebo 0.3
Normalized name: Norethindrone;Placebo 0.35 MG; NA Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0.3 mg/m(3)
Study: 18615480
Drug: CC haplotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC haplotype of ERCC1
Study: 10423632
Drug: 60 microg
Normalized name: Filgrastim 960 microgram/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 microg PGE (1) administered intravenously (i.v.) in 100 mL saline solution over 2 hours each day for 14 days.
Study: 10423632
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously (i.v.) in 100 mL saline solution over 2 hours each day for 14 days.
Study: 3549323
Drug: Zopiclone 7.5
Normalized name: zopiclone 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone 7.5 mg given orally at bedtime for 7 consecutive days
Study: 3549323
Drug: Triazolam 0.5
Normalized name: triazolam 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.5 mg given orally at bedtime for 7 consecutive days
Study: 30043714
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg tamsulosin plus 10 mg tadalafil daily for 7 days
Study: 30043714
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg tamsulosin plus placebo
Study: 22651946
Drug: Guideline-based parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-based parenteral hydration therapy
Study: 18822977
Drug: Acupoint-injection group
Normalized name: meningococcal group B vaccine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint-injection group (2 mg Morphine into bilateral Neiguan (PC 6))
Study: 18822977
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection group (5 mg Morphine)
Study: 18822977
Drug: Hypodermic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypodermic injection group (5 mg Morphine)
Study: 14695923
Drug: CoQ10 100
Normalized name: Walgreens CoQ10 100mg Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 100 mg t.i.d.
Study: 27488394
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg ramosetron
Study: 11348910
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl
Study: 11911558
Drug: Tramadol/acetaminophen
Normalized name: TRAMADOL/ACETAMINOPHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol/acetaminophen
Study: 22760642
Drug: Milk fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk fortified with 10 mg Fe/L as ferrous sulfate
Study: 22760642
Drug: Milk fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk fortified with 10 mg Fe/L and 5 mg Zn/L as Zn sulfate
Study: 22760642
Drug: Milk fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk fortified with 10 mg Fe/L and 10 mg Zn/L as Zn sulfate
Study: 22760642
Drug: Milk fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk fortified with 10 mg Fe/L and 20 mg Zn/L as Zn sulfate
Study: 22760642
Drug: Milk fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk fortified with 10 mg Fe/L and ascorbic acid (70 mg/L)
Study: 22760642
Drug: Milk fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk fortified with 10 mg Fe/L and 5 mg Zn/L as Zn sulfate and ascorbic acid (70 mg/L)
Study: 22760642
Drug: Milk fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk fortified with 10 mg Fe/L and 10 mg Zn/L as Zn sulfate and ascorbic acid (70 mg/L)
Study: 22760642
Drug: Milk fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk fortified with 10 mg Fe/L and 20 mg Zn/L as Zn sulfate and ascorbic acid (70 mg/L)
Study: 12133500
Drug: Bifendate (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifendate (higher doses: 30-45 mg/d for ages <= 12, 45-67.5 mg/d for ages > 12) for up to 12 months
Study: 12133500
Drug: Bifendate (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifendate (higher doses)
Study: 7575719
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody (MAb) CAMPATH‐1H treatment
Study: 1710655
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin (40 mg/m2 daily for 5 days)
Study: 1710655
Drug: Standard-dose cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose cisplatin (20 mg/m2 daily for 5 days)
Study: 8113843
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin
Study: 1710655
Drug: Standard-dose cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose cisplatin
Study: 7233157
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium water (107 mg Na/L)
Study: 30293198
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (70 µg [2800 IU] daily for 3 months)
Study: 27798013
Drug: PCV7 (7-valent
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV7 (7-valent pneumococcal conjugate vaccine)
Study: 19129748
Drug: Dapagliflozin (2.5-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (2.5-100 mg daily for 14 days)
Study: 19129748
Drug: Dapagliflozin (20-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (20-50 mg)
Study: 15512856
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg PAS